Collaboration and Licensing Revenue - Additional Information (Details) - USD ($)	1 Months Ended			5 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	May 31, 2016
Exotech Bio, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement			90 days
Exotech Bio, Inc. | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product			$ 52,500,000
Exotech Bio, Inc. | Upfront | Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value			$ 5,000,000
Relieve Genetics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement			90 days
Relieve Genetics, Inc. | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product			$ 52,500,000
Relieve Genetics, Inc. | Upfront | Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value			$ 4,333,000
Intrexon T1D Partners
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement			90 days
Intrexon T1D Partners | Upfront | Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value			$ 10,000,000
AD Skincare, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement		90 days
AD Skincare, Inc. | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product		$ 2,000,000
Milestone payments to be received upon successful achievement, one-time		17,000,000
AD Skincare, Inc. | Upfront | Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value		$ 4,333,000
ZIOPHARM Oncology, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty rate as a percentage of net profit		20.00%		50.00%
ZIOPHARM Oncology, Inc. | Other Contractual Payments | Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value		$ 120,000,000
Collaborative arrangement consideration received, number of preferred shares (in shares)		100,000
Genten Therapeutics, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement	90 days
Genten Therapeutics, Inc. | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product	$ 82,000,000
Genten Therapeutics, Inc. | Upfront | Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value	3,000,000
Collaborative arrangement consideration received in the form of cash	$ 1,500,000
CRS Bio, Inc.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Required notice period for voluntary termination of collaborative agreement	90 days
CRS Bio, Inc. | Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments to be received upon successful achievement, per product	$ 75,000,000
CRS Bio, Inc. | Upfront | Upfront and Milestone Payments
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement consideration received, value	$ 2,100,000